

DENOSUMAB solution for injection (Prolia®) for bone loss associated with long-term systemic glucocorticoid therapy

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DENOSUMAB solution for injection (Prolia®) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy.

Denosumab (Prolia®) has recently been granted a license extension and is now indicated for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.^[1]

This new indication was not identified during horizon scanning. NICE has agreed the final protocol for a Multiple Technology Appraisal (MTA) for [Non-bisphosphonates for the prevention of osteoporotic fragility fractures](#) and this will assess use of these agents in current or frequent recent use of oral or systemic glucocorticoids, including people under 50 years of age. Therefore, this recommendation will be reviewed once the NICE MTA is published.

In the meantime, clinicians should continue to follow current clinical practice for managing bone loss associated with long-term systemic glucocorticoid therapy:

- > Clinical Knowledge Summaries (CKS): [Osteoporosis – prevention of fragility fractures](#) (last revised July 2016)

Reference:

1. Amgen Ltd. Summary of Product Characteristics [Prolia](#), 08 June 2018. Accessed online 28 August 2018.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.